Medicare Rx Card Fraud Rule
This article was originally published in The Pink Sheet Daily
The HHS Office of Inspector General has finalized a rule governing imposition of civil monetary penalties against Medicare-endorsed drug discount card sponsors that engage in prohibited practices
You may also be interested in...
An interim final rule providing for civil monetary penalties that may be imposed against Medicare-endorsed card sponsors is scheduled for publication May 19.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.